The survey-submitted biomarker results varied in detail and depth (Supplementary Data 2), but common genetic markers were apparent across good predictions in SC1B, including EGFR, ERBB2, PIK3CA, PTEN, TP53, or RB1. In the survey, synergy was commonly assigned to drug pairs targeting directly down- or up-stream of a mutated, amplified, overexpressed or deleted cancer gene. This evidence concerns the gene PTEN and cancer.